ClinicalTrials.gg
RecruitingNCT07104942Updated Aug 24, 2025

Effect of Expiratory Muscle Strength in Patients With Bronchiectasis

An observational study in Bronchiectasis, sponsored by Nisanur Tutuş. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Nisanur Tutuş · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
64
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Bronchiectasis with a site in Turkey — 10 open to participants now, 11 under way, 2 of them phase 3. Bronchiectasis · Turkey.

Planned enrollment
5th of 12
64 · median 60
Started
2025
with 6 others
Observational
12 of 36
2 open now
Primary completion
2025-12
later than 0 of 10 live
Registered
30th of 36
by date

Among the 36 studies in Bronchiectasis with a site in Turkey, this one is the 5th largest by planned enrollment of the 12 observational ones that give a count, is one of 7 that started in 2025, is one of 12 observational ones, reaches primary completion later than 0 of the 10 other live ones, and was the 30th registered.

Bronchiectasis

405 studies on the registry are indexed under Bronchiectasis; 126 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

10 of the 36 studies in Bronchiectasis with a site in Turkey are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 94 Bronchiectasis studies recruiting now, 51 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 13 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Bronchiectasis with a site in Turkey, or all of them as a file.
02

Study summary

This study investigates the relationship between expiratory muscle strength and clinical outcomes such as disease severity, hospital admissions, and quality of life in individuals with bronchiectasis.

Read the detailed description

This study aims to examine the relationship between expiratory muscle strength and clinical outcomes such as disease severity, hospital admission history, and quality of life in individuals with bronchiectasis. Effective coughing is a critical physiological reflex for airway clearance; however, the relationship between expiratory muscle strength and cough effectiveness in the bronchiectasis population has not been clearly established. Identifying expiratory muscle weakness as a potential contributor to increased symptom burden and impaired airway clearance may improve clinical understanding and support the development of targeted physiotherapy interventions. The findings of this study could serve as a foundation for future interventional research in pulmonary rehabilitation and respiratory muscle training for this population.

03

Conditions studied

  • Bronchiectasis

Browse trials for

Keywords

  • Bronchiectasis
  • Expiratory muscle strength
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Süreyyapaşa Chest Diseases and Chest Surgery Training and Research Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having a diagnosis of non-cystic fibrosis bronchiectasis
  • Without an acute infection at the time of assessment (confirmed by medical history, serum C-reactive protein levels, chest X-ray and/or HRCT).
  • Being between 18 and 65 years of age

Exclusion criteria

Exclusion Criteria:

  • Myopathies
  • Stroke (Cerebrovascular accident - CVA)
  • Pregnancy
  • Unstable cardiac disease
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
64 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Respiratory Muscle Strength

    Respiratory muscle function will be assessed by measuring maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) in the sitting position using a mouth pressure device (MEC PFT Systems Pocket-Spiro).

    Time frame: Baseline

Secondary outcomes

  1. Modified Medical Research Council Dyspnea Score

    Modified Medical Council Dyspnea score will rate the sensation of dyspnea as the person perceives it.The severity of dyspnea is rated on a scale of 0 to 4."0 point" means no dyspnea perception and "4 point" means severe dyspnea perception.

    Time frame: Baseline

  2. Leicester Cough Questionnaire

    This is a short questionnaire that assesses quality of life, particularly for chronic cough. It is relatively easy to administer. The Leicester Cough Questionnaire consists of nineteen questions assessing three different areas: physical, social, and psychological. Scores for the LCQ include mean scores for each domain (ranging from 1 to 7) and a total score calculated as the sum of the domain scores (ranging from 3 to 21). Higher scores indicate better quality of life.

    Time frame: Baseline

  3. Bronchiectasis Severity Index

    The Bronchiectasis Severity Index (BSI) will be used to determine disease severity. This index examines nine parameters: age, body mass index, % predicted FEV1, hospitalizations due to exacerbations in the last 2 years, number of exacerbations in the previous year, level of dyspnea, colonization by Pseudomaonas and other microorganisms, and radiological findings. These scores classify patients into mild (0-4 points), moderate (5-8 points), and severe (9 points and above) groups and identify patients at risk of death, hospitalization and exacerbations.

    Time frame: Baseline

  4. Hospital Anxiety Depression Scale

    This is a 14-item scale developed by Zigmond and Snaith. Seven of these items assess anxiety symptoms, and seven assess depression symptoms. The items in the scale are assessed using a 4-point Likert scale and are based on a scoring system ranging from 0 to 3. Scores range from 0 to 21 for each subscale and can be summed to yield a total anxiety-depression score of up to 42. Higher scores indicate increased symptom severity, while a cut-off score of 8 indicates high levels of depression and anxiety symptoms.

    Time frame: Baseline

  5. Fatigue severity scale

    Individuals' fatigue levels will be assessed using the Fatigue Severity Scale (FSS). The FSS consists of 9 questions scored on a 7-point Likert scale, indicating a perceived level of fatigue that may require medical attention. It is a valid and reliable instrument, with a score of 7 being associated with greater fatigue.

    Time frame: Baseline

  6. Spirometric measurements (Forced vital capacity)

    It is used to evaluate respiratory functions. It is evaluated with a spirometer. Forced vital capacity (FVC): the maximum amount of air that can be forcibly exhaled from the lungs after fully inhaling. It can be recorded in percentages or liters.

    Time frame: Baseline

  7. Spirometric measurements (First second forced expiratory volume)

    It is used to evaluate respiratory functions. It is evaluated with a spirometer. First-second forced expiratory volume (FEV1): the amount of air that can be exhaled with force in 1 second. It can be recorded in percentages or liters.

    Time frame: Baseline

  8. Spirometric measurements (FEV1/FVC ratio)

    It is used to evaluate respiratory functions. It is evaluated with a spirometer. It is calculated by dividing FEV1 by FVC. It is expressed as a percentage.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Dec 2025, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Aug 5, 2025
StartEst.
Aug 2025
Primary completionEst.
Dec 2025
CompletionEst.
Jun 2026
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07104942
Lead sponsor
Nisanur Tutuş
Responsible party
Nisanur Tutuş (Principal Investigator, Saglik Bilimleri Universitesi) — Sponsor-investigator
First posted
Aug 5, 2025
Start date
Aug 2025 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Jun 2026 (estimated)
Last update
Aug 24, 2025

Study contacts

Nisanur Tutuş
Contact
nisanurtutuss@gmail.com
(0216) 421 42 00 ext. 1352

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion